Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials.
To test the predictive values in clinical progression of neuropathology change (amyloid …

Dementia and mortality rates rise inexorably with age and consequently interact. However,
because of the major logistical difficulties in accounting for both outcomes in a defined …

Background and Objectives It is unclear to what extent cognitive outcome measures are
sensitive to capture decline in Alzheimer disease (AD) prevention trials. We aimed to …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited available
therapies. There is progress in developing treatments for neuropsychiatric indications in AD …

Measures of change in hippocampal volume derived from longitudinal MRI are a well-
studied biomarker of disease progression in Alzheimer's disease (AD) and are used in …

Providing an accurate prognosis for individual dementia patients remains a challenge since
they greatly differ in rates of cognitive decline. In this study, we used machine learning …

Objective To study risk factors for decreasing aβ1–42 concentrations in cerebrospinal fluid
(CSF) in cognitively unimpaired individuals with initially normal amyloid and tau markers …

The Remote Assessment of Disease and Relapse–Alzheimer's Disease (RADAR-AD)
consortium evaluated remote measurement technologies (RMTs) for assessing functional …

Background As investigations of disease modifying drugs aim to slow down progression of
Alzheimer'disease (AD) biomarkers to reliably track disease progression gain more …

Increasing interest in clinical trials and clinical research settings to identify Alzheimer's
disease (AD) in the earliest stages of the disease has led to the concept of preclinical AD …